What Standard Tests Miss
Standard lipid panels report LDL cholesterol (LDL-C), which estimates the total amount of cholesterol carried by LDL particles. But cholesterol is merely the cargo — what matters more for cardiovascular risk is the number of LDL particles themselves. Each particle has the potential to become oxidised, enter the arterial wall, and initiate the inflammatory cascade that leads to plaque formation.
ApoB: The Particle Counter
Apolipoprotein B (ApoB) is the structural protein present on every atherogenic particle — LDL, VLDL, IDL, and Lp(a). Measuring ApoB gives you a direct count of the total number of these particles, whereas LDL-C only tells you the mass of cholesterol inside them. When particles are small and dense — which is common in insulin resistance — LDL-C can appear normal while particle count is dangerously high.
The Discordance Problem
A person with metabolic syndrome may have an LDL-C of 120 mg/dL (considered acceptable by conventional guidelines) but an ApoB of 130 mg/dL (high risk) because their LDL particles are small and numerous. This pattern, called hyperapoB, is a hallmark of atherogenic dyslipidemia — and standard panels miss it completely.
If you have insulin resistance, prediabetes, or type 2 diabetes, ApoB is unequivocally the superior risk marker.
Why It Matters for Metabolic Health
ApoB captures risk from all atherogenic particles — LDL, VLDL, IDL, and Lp(a)
ApoB is not confounded by the particle size shift that occurs in metabolic syndrome
Every ApoB-containing particle is one potential plaque-initiating event
Guidelines increasingly recommend ApoB as the primary lipid target for high-risk populations
Lp(a) — a genetically determined, highly atherogenic particle — is measured alongside ApoB for a complete picture
Reducing ApoB: Beyond Statins
Reduce refined carbohydrate intake — lowers hepatic VLDL production, the precursor to LDL particles
Increase omega-3 fatty acids (EPA/DHA) — improves particle size profile